Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Naltrexone And Bupropion

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)

Orexigen Therapeutics, Inc · Phase 2/3 · Completed · Enrollment 92

NCT04599478

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medicationn/rn/rn/rn/r
BWL + Placebon/rn/rn/rn/r
NB medicationn/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication: endpoint not reported
  • BWL + Placebo: endpoint not reported
  • NB medication: endpoint not reported
  • Placebo: endpoint not reported